{"id":"NCT01702571","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment","officialTitle":"A Two-Cohort, Open-Label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-Based Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11-27","primaryCompletion":"2020-07-31","completion":"2020-07-31","firstPosted":"2012-10-08","resultsPosted":"2021-08-05","lastUpdate":"2022-04-04"},"enrollment":2185,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Trastuzumab Emtansine","otherNames":["RO5304020, T-DM1, Kadcyla"]}],"arms":[{"label":"Trastuzumab Emtansine (All Participants)","type":"EXPERIMENTAL"},{"label":"Trastuzumab Emtansine (Asian Participants)","type":"EXPERIMENTAL"}],"summary":"This two-cohort, open-label, multicenter study will assess the safety, efficacy and tolerability of trastuzumab emtansine in participants with HER2-positive locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) who have received prior anti-HER2 and chemotherapy-based treatment. Participants in Cohort 1 will be drawn from the general participant population; Cohort 2 will include only Asian participants.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events of Primary Interest (AEPIs)","timeFrame":"Baseline up to approximately 7 years","effectByArm":[{"arm":"Trastuzumab Emtansine (All Participants)","deltaMin":23.1,"sd":null},{"arm":"Trastuzumab Emtansine (Asian Participants)","deltaMin":51.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":17},"locations":{"siteCount":300,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","China","Croatia","Denmark","Dominican Republic","Ecuador","Estonia","Finland","France","Germany","Greece","Guatemala","Hong Kong","Hungary","Iceland","Indonesia","Ireland","Italy","Luxembourg","Mexico","Netherlands","Norway","Panama","Peru","Poland","Portugal","Slovakia","Slovenia","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Arab Emirates","United Kingdom","Venezuela"]},"refs":{"pmids":["36084395","34741021","32634611"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":427,"n":2002},"commonTop":["NAUSEA","FATIGUE","ASTHENIA","HEADACHE","EPISTAXIS"]}}